SPY400.09-1.63 -0.41%
DIA322.78+0.55 0.17%
IXIC11,662.79-142.21 -1.20%

Pfizer's Phase 2/3 Trial of Paxlovid for Post-exposure Prophylactic Use Fails to Meet Primary Goal

MT Newswires · 05/02/2022 00:52

Please log in to view news